ArticleCureus2025

Intra-Class Interleukin-(IL)-17 Blocker Switching: Ixekizumab as a Solution for Secukinumab Non-responders in Secondary Biologic Failure in Psoriasis.

Abhishek De et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.